Participated · Series A · Aug 2023

Wonder Brands pivoted from buying established sellers to acquiring e-commerce infrastructure and developing its own digital brands across marketplaces like MercadoLibre and Amazon. The company uses marketplace data plus AI-driven operations, marketing, analytics, supply-chain and working-capital tools to create and scale products. In the past 12 months it launched more than 15 brands and introduced over 2,000 SKUs, with plans to double SKUs in the next year and enter new product categories. Wonder Brands reached profitability in 2022 and is generating over $100 million in annualized revenues with an annual growth rate exceeding 100%. It currently operates in Mexico, Colombia, Chile, Argentina and Uruguay and plans to use new capital to expand into the rest of South America, hire staff, build distribution channels and invest in go-to-market. Wonder Brands acquires digitally native sellers on MercadoLibre, Amazon and other marketplaces and uses technology and operating support to scale them. The company offers category and brand management, marketing and performance, inventory and logistics automation, and channel operations. It focuses on home & garden, sports & fitness, and beauty & personal care. Founded in January 2021 by Nicolás Gonzalez Luna and Federico Malek, the company currently has 20 employees and plans to triple headcount in the next month. Wonder Brands targets larger sellers (at least $5M in revenue) using a buy-and-build approach rather than pure consolidation. The company aims to reach $55 million in revenue by year-end and $100 million within the following 12 months, and plans to begin operations in Brazil by the end of 2021.

Participated · Seed · Mar 2023

AERA Health offers a hybrid model that brings data-driven P4 medicine to consumers via existing healthcare infrastructure. Its platform integrates personalised health data, counsel from medical professionals, and technology to enable predictive, preventive, personalised, and participatory care. The company will use the recent funding to roll out its platform and hire new team members. AERA will initially serve customers in the DACH region and is opening its first physical treatment space in Munich in April. It plans additional physical spaces offering health checks, ortho-biologics, and longevity medicine services throughout 2023. The round reportedly places the company at a valuation in the “mid 20's” region.

Participated · Series B · Oct 2022

Alto Neuroscience is a Mountain View, CA–based clinical-stage biopharmaceutical company focused on precision psychiatry therapies that pair digital biomarkers with novel CNS drugs. Its lead candidate, ALTO-207—a fixed-dose combination of pramipexole and ondansetron—hit primary and secondary endpoints in a 32-patient Phase 2a study for treatment-resistant depression and is slated to enter Phase 2b by mid-2026 and Phase 3 in early 2027. The firm also advances ALTO-101, which recently secured FDA Fast Track status for cognitive impairment associated with schizophrenia. Alto’s platform employs electroencephalography and cognitive testing to tailor treatments to individual patients. The company carries a market capitalization of about $164.6 million and reports a strong liquidity profile, with a current ratio of 18.43 and more cash than debt, though it is experiencing rapid cash burn. The newly raised capital should extend its runway and fund upcoming clinical milestones.

Participated · Equity · Sep 2022

Gameto develops stem cell-derived therapies for reproductive health, with its lead program Fertilo using iPSC-derived engineered ovarian support cells to mature eggs outside the body. Fertilo is cleared for commercialization in multiple ex-U.S. jurisdictions (Peru, Mexico, Australia, Japan, India, Singapore, Guatemala, Argentina, Dominican Republic, and Paraguay) and has been used in clinics with five babies born and over 20 pregnancies recorded. The therapy shortens standard ovarian stimulation from about two weeks of daily hormone injections to 2–3 days and is the first iPSC-derived therapy to reach late-stage clinical development in the U.S. Gameto is conducting a randomized, controlled, double-blind Phase 3 trial (FIRST) at up to 20 U.S. sites with an anticipated interim readout in late 2026. Beyond Fertilo, the company is developing the ARPA-H-funded Ameno menopause program, which includes an implantable cell therapy and a next-generation vaginal ring planned for Phase 1. Gameto's platform is built on an AI-powered in vitro organoid system developed with George Church's lab, and the company has raised $127 million to date. Gameto develops Fertilo, a novel investigational in vitro maturation (IVM) solution that uses engineered ovarian support cells (OSCs) to mature eggs outside the body. The company aims to make IVF and egg freezing shorter, safer, and more accessible by reducing hormonal injections. Gameto is led by CEO Dr. Dina Radenkovic and is already using Fertilo in clinical settings in Australia and Latin America. Following discussions with the U.S. Food and Drug Administration, Gameto received tentative approval to proceed to Phase 3 trials subject to completion of certain assay and manufacturing requirements. The recent financing will support clinical development of Fertilo and continued commercial launches in markets where it is in use. Financially, the company reported a $33M Series B that brought total funding to $73M. Gameto is a biotechnology company using cell engineering to develop therapeutics for diseases of the female reproductive system. Its underlying cell‑engineering platform was developed in stealth under a scientific research agreement with George Church’s lab at Harvard Medical School. The company is led by Dr. Dina Radenkovic and operates out of New York City and Madrid. In January it announced three sequenced programs: Fertilo (a biologic for IVF and egg freezing), Deovo (an organoid of the female reproductive system), and Ameno (a cell‑based therapeutic for primary ovarian insufficiency and menopause). Fertilo has entered preclinical development in partnership with clinics in the US and Spain, and partner clinics named include Extend Fertility, RMA, Pozitivf, Ovation Fertility, Clinica Tambre, and Hospital Ruber Internacional. Gameto intends to use the new funding to expand operations and broaden its business reach. Gameto is developing a platform for ovarian therapeutics that targets accelerated ovarian aging to change the trajectory of women’s health and equality. Its initial focus is on addressing menopause and improving assisted fertility through three sequenced programs: Fertilo, Deovo and Ameno. Fertilo aims to improve assisted fertility with a long-term mission to eliminate infertility; Deovo is initiating drug discovery and a computational platform for ovarian aging; Ameno aims to make the medical burden of menopause optional. The company is led by CEO Dr. Dina Radenkovic with Martin Varsavsky as chairman and is based in New York City and Boston, Massachusetts. Financially, Gameto disclosed a $20M Series A and a prior $3M seed (March 2020), totaling $23M in disclosed funding.